Skip to content
PeptideGeek

Weight loss

Orforglipron, explained simply

A daily pill for weight loss and diabetes — the first GLP-1 drug that's a simple small molecule instead of an injection. In late-stage trials.

Well studied in peopleTaken by mouth8 cited sources

Start here

What is Orforglipron?

Orforglipron is a once-daily weight-loss pill — the first GLP-1 (a gut hormone that tells your brain you're full) medicine that is a small molecule rather than a peptide, so it needs no injections and no food or water restrictions 7. It activates the same GLP-1 receptor as injectable drugs like semaglutide, lowering appetite so people eat less 7. The FDA approved it in April 2026, under the brand name FOUNDAYO, for long-term weight reduction in adults with obesity, or with overweight plus at least one weight-related condition; it is not approved for type 2 diabetes. In trials, adults without diabetes lost 11.1% of body weight on average at 72 weeks on the top dose, versus 2.1% on placebo 7.

How it works in your body

Orforglipron is a small-molecule (non-peptide) drug, taken as a once-daily pill, that activates the GLP-1 (a gut hormone that tells your brain you're full) receptor — the same receptor injectable drugs like semaglutide act on — so people eat less, likely because appetite falls. 7

The deeper mechanism, for the curious

Orforglipron is a non-peptide GLP-1 receptor agonist (a small-molecule drug that switches on the receptor for GLP-1, a gut hormone that controls appetite and blood sugar). It binds to and activates the human GLP-1 receptor. 7 GLP-1 receptors are present in brain regions that control appetite. In animal studies orforglipron reached and activated nerve cells in those regions, and in people it lowers food intake, likely by lowering appetite. 7 It slows gastric emptying (how fast the stomach empties), most after the first dose and less over time, and the weight lost is more fat than lean mass (muscle and other non-fat tissue). 7 It is broken down mainly by CYP3A4 (a liver enzyme), reaches its peak level in the blood 4–8 hours after a dose, and has an elimination half-life (the time the body takes to clear half the drug) of about 29–49 hours. 7

Evidence check

Well studied in people

This has been through large human trials — the strongest kind of evidence. Scientists have tested it on many people and measured what actually happened.

Every numbered marker on this page links to one of the 8 sources at the bottom.

9/100

Weight Management

11.1% average weight loss at 72 weeks on the top 17.2 mg dose against 2.1% on placebo, with 54.5% losing at least 10% of body weight (13% on placebo), in 3,127 adults without diabetes — from a once-daily pill

9/100

Blood Sugar Control

HbA1c (average blood sugar) reduction of 2.2% in the ACHIEVE-3 trial, beating oral semaglutide (1.4%), with nearly 3x more patients reaching a target HbA1c below 7%

7/100

Cardiovascular Health

50.6% reduction in hsCRP (a blood marker of inflammation) at the 36 mg dose, along with improvements in non-HDL cholesterol, triglycerides (blood fats), and systolic blood pressure (the top number)

What the research points to

The most-asked question

How much Orforglipron do I take?

Orforglipron is dose-escalated: the studies start everyone low and step the dose up on a schedule, so the right amount depends on the week you're on. The research-reported maintenance range is 0.8–17.2 mg, once daily.

  1. At least 30 days

    0.8 mg once daily

    • How often
      Once daily, with or without food
    • Used for
      Weight management, GI-sensitive patients
    • How
      By mouth

    Label starting dose. After at least 30 days, increase to 2.5 mg once daily, then after at least 30 more days to 5.5 mg once daily; gradual escalation reduces gastrointestinal reactions 7. Tablets are swallowed whole, one per day 7.

  2. Ongoing, reached after at least 30 days each on 0.8 mg and 2.5 mg

    5.5 mg once daily

    • How often
      Once daily, with or without food
    • Used for
      Weight management, Type 2 diabetes (investigational)
    • How
      By mouth

    First maintenance-level dose on the label's escalation 7. In the phase 3 trial without diabetes, 5.5 mg produced 7.4% average weight loss at 72 weeks against 2.1% on placebo 7.

  3. Ongoing; each step after at least 30 days on the previous dose

    9–17.2 mg once daily

    • How often
      Once daily, with or without food
    • Used for
      Maximal weight reduction, Cardiometabolic risk improvement
    • How
      By mouth

    Optional further steps of 9 mg, 14.5 mg and 17.2 mg based on response and tolerability; 17.2 mg is the maximum, and 9 mg is the maximum alongside a strong CYP3A4 inhibitor 7. 17.2 mg produced 11.1% average weight loss at 72 weeks against 2.1% on placebo 7.

Adjusting your dose

You're at the right dose if…

  • Therapeutic goals being met with minimal side effects
  • Stable and consistent response to treatment
  • Lab values or clinical markers trending in the right direction
  • Good tolerance with manageable or absent side effects

Consider going up if…

  • You've tolerated the current dose for the recommended period without significant side effects
  • Therapeutic goals haven't been met at the current dose level
  • Your healthcare provider recommends dose escalation based on your response
  • Lab work or clinical assessments support a higher dose

Go down if…

  • Side effects are bothersome or impacting daily life despite management strategies
  • You experience any signs of an adverse reaction
  • Lab results indicate the need for dose reduction
  • Your healthcare provider recommends a lower dose based on your response

The ceiling: 17.2 mg once daily — the label maximum; 9 mg when taken with a strong CYP3A4 inhibitor 7

Reconstitution, in plain words

How do I mix Orforglipron?

Peptides usually arrive as a freeze-dried powder in a small vial. “Reconstitution” just means adding sterile water back in so you can measure a dose. Here's how it works for Orforglipron:

What you need

  • Orforglipron in its prescribed form
  • Clean, dry storage container
  • Measuring device if applicable (oral syringe, measuring cup)
  • Calendar or reminder app for dosing schedule

A worked example

Orforglipron comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.

Working out your dose

Use Orforglipron exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.

Or let the calculator do it

Three quick questions — your vial, your water, your dose — and it tells you the exact syringe mark. “Find dose amount” is preloaded with Orforglipron's recorded schedule.

OrforglipronOnce daily, with or without food

How much peptide is in your bottle?

Look at the label on the vial. It’s the number next to the unit — like "5 mg". Labeled in IU? Switch the unit to IU.

Type a number to continue.
0

Timing

When do I take Orforglipron?

Best time of day

Take Orforglipron at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.

With or without food?

Orforglipron can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.

Taking it with other peptides

Orforglipron should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.

The honest list

What side effects could Orforglipron cause?

Common — usually mild

These show up most often. They usually fade as your body adjusts.

  • Nausea

    The most commonly reported adverse event, in line with other GLP-1 (a gut hormone that tells your brain you're full) drugs. Dose-dependent and most frequent while the dose is being increased. 7 Generally mild to moderate.

    What to do Gradual dose escalation minimizes incidence. Symptoms typically improve with continued treatment. Smaller, more frequent meals may help. If severe, pause escalation at current dose level.

  • Constipation

    Common gastrointestinal effect related to GLP-1R-mediated slowing of gut motility. Reported across dose levels in Phase 3 trials. 7

    What to do Increase dietary fiber and fluid intake. Mild laxatives if needed. Usually manageable and does not require dose adjustment.

  • Diarrhea

    Gut upset caused by GLP-1 (a gut hormone that tells your brain you're full) activation, which affects how the intestines move and secrete. Generally temporary and goes away on its own.

    What to do Maintain hydration. Usually resolves without intervention. Contact prescriber if persistent or severe.

  • Vomiting

    Occurs alongside nausea, particularly during dose titration (stepping the dose up gradually). Related to central and peripheral GLP-1R activation.

    What to do Slow dose escalation. Ensure adequate hydration. Anti-emetics if needed. Temporarily hold dose increase if recurrent.

Less common

Worth knowing about, but most people never see these.

  • Heart Rate Increase

    Average heart rate rose 4 to 5 beats per minute from baseline versus 0.5 on placebo, and a fast heart rate (tachycardia (a racing heart rate)) was reported in 3% versus 0.9%. 7 An expected effect across GLP-1 (a gut hormone that tells your brain you're full) drugs of this class.

    What to do Monitor heart rate at clinical visits. Not clinically significant in most patients. Expected pharmacological effect that has been associated with cardiovascular benefit in other GLP-1 (a gut hormone that tells your brain you're full) RA outcomes trials.

Serious — stop and get medical help

Rare, but if any of these happen, stop and contact a medical professional.

Week by week

What should I expect from Orforglipron, and when?

  1. Weeks 1-8

    You might notice
    • Dose escalation period from 3 mg to target maintenance
    • GI side effects (nausea, constipation) peak during this phase
    • Early appetite reduction and initial weight loss
    What's normal
    • Nausea is common and expected during dose titration (stepping the dose up gradually)
    • Appetite naturally decreases as GLP-1R activation increases
    • Early weight loss of 2-4% may occur
    • GI symptoms gradually improve as the body adjusts
    What's next
    • Reach target maintenance dose (12 or 36 mg)
    • GI tolerability typically improves significantly after dose stabilization

  2. Weeks 8-24

    You might notice
    • Steady weight loss speeds up at the maintenance dose
    • HbA1c (a blood test of average blood sugar over about 3 months) improvements become measurable
    • GI side effects largely resolved
    • Reduced appetite stabilizes
    What's normal
    • Weight loss of 5-8% at this timepoint
    • HbA1c (a blood test showing average blood sugar over the past three months) dropping significantly in people with type 2 diabetes
    • Blood pressure and blood fat (lipid) improvements beginning
    • Most patients tolerate the medication well
    What's next
    • Continue the maintenance dose
    • An HbA1c (a blood test showing average blood sugar over the past three months) check at 12-16 weeks shows the total blood sugar benefit so far

  3. Weeks 24-72

    You might notice
    • Continued weight loss approaching 10-12% at 36 mg
    • Sustained metabolic improvements
    • Cardiovascular risk markers (hsCRP, lipids, BP) showing significant improvement
    What's normal
    • In ATTAIN-1 trial, 12
    • 4% weight loss at 36 mg over 72 weeks
    • 65% of patients achieved >10% weight loss
    • 6% reduction in hsCRP (a blood marker of inflammation)
    • HbA1c (average blood sugar) reductions sustained
    What's next
    • Long-term maintenance
    • Phase 3 cardiovascular outcomes trial (ATTAIN-Outcomes) will define long-term cardiovascular benefit

How to tell it's actually working

Treatment Response

  • Improvement in the primary symptoms or condition being treated
  • Positive changes in relevant lab values or clinical markers
  • Consistent, stable response to Orforglipron over time
  • Reduction in symptom frequency or severity

General Well-being

  • Improved energy levels and daily functioning
  • Better quality of life related to the treated condition
  • Manageable or absent side effects indicating good tolerance
  • Positive feedback from healthcare provider during check-ups

Not seeing anything? The usual reasons

  • Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
  • Insufficient time at target dose—most compounds need several weeks to show full benefits
  • Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
  • Individual variation in response—genetics, metabolism, and other factors affect outcomes
  • Underlying conditions or medications interfering with absorption or effectiveness
  • Improper storage leading to degraded product—always verify proper storage conditions

Is it right for you?

Who should avoid Orforglipron?

Do not use it if…

Be extra careful if…

  • You are taking other medications—discuss potential interactions with your healthcare provider
  • You have a history of liver or kidney disease
  • You are elderly or have multiple medical conditions
  • You are planning surgery in the near future—inform your surgeon about Orforglipron use
  • You have any chronic health conditions that require regular monitoring

When to stop

  • Severe or worsening side effects that don't improve with dose adjustment or supportive care
  • Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
  • Your healthcare provider recommends discontinuation based on your clinical response
  • Development of any new medical condition that may be contraindicated with Orforglipron
  • Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
  • Abnormal lab results or clinical markers that suggest adverse effects

Orforglipron should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.

What it mixes badly (and well) with

Medications

  • Avoid
    Injectable GLP-1 Receptor Agonists

    Both switch on the same GLP-1 (a gut hormone that tells your brain you're full) receptor, so there is no added benefit and more stomach and gut side effects

  • Avoid
    DPP-4 Inhibitors

    Both boost the same gut-hormone (incretin) pathway, so combining them adds little benefit when you already take a drug that directly activates the GLP-1 (a gut hormone that tells your brain you're full) receptor

  • Avoid
    Sulfonylureas

    Higher risk of hypoglycemia (dangerously low blood sugar), because sulfonylureas release insulin whatever your blood sugar is, on top of the insulin release triggered by the GLP-1 (a gut hormone that tells your brain you're full) receptor

Other peptides

  • OK together
    Metformin

    They work in different ways. Metformin helps your body respond better to insulin. Orforglipron activates the GLP-1 (a gut hormone that tells your brain you're full) receptor (the docking site for a gut hormone that controls appetite and blood sugar), which releases insulin only when blood sugar is high and lowers appetite.

  • OK together
    SGLT2 Inhibitors

    Lowers blood sugar a different way, by making the kidneys pass sugar out in urine, with shown heart and kidney benefits. It complements orforglipron, which acts like the GLP-1 (a gut hormone that tells your brain you're full) gut hormone and can be taken by mouth.

  • OK together
    Dietary Modification

    Eating fewer calories adds to orforglipron's appetite reduction for more weight loss

Supplements

  • OK together
    Multivitamins

    Generally safe to take alongside Orforglipron. Space doses apart if taking oral formulations to ensure optimal absorption.

  • OK together
    Electrolyte supplements

    Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.

Who it tends to suit

A pill that works like the GLP-1 gut hormone (which controls appetite and blood sugar), with no injections

Orforglipron is particularly well-suited for individuals focused on a pill that activates the GLP-1 (a gut hormone that tells your brain you're full) receptor (a hormone signal for appetite and blood sugar) without injections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Weight management in obesity with or without type 2 diabetes

Orforglipron is particularly well-suited for individuals focused on weight management in obesity with or without type 2 diabetes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Blood sugar control in type 2 diabetes, added to metformin

Orforglipron is particularly well-suited for individuals focused on glycemic control (keeping blood sugar steady) in type 2 diabetes as add-on to metformin. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Lower heart and blood vessel risk through weight loss and better metabolism

Orforglipron is particularly well-suited for individuals focused on cardiovascular risk reduction through weight loss and metabolic improvements. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

The safety picture overall

Orforglipron is FDA approved as FOUNDAYO (April 2026) for long-term weight management. 78 Its label carries a boxed warning (the FDA's strongest warning) about thyroid C-cell tumours (tumours in thyroid hormone-making cells) seen with GLP-1 (a gut hormone that tells your brain you're full) drugs in rodents — orforglipron itself is not active in rats or mice and caused no rodent tumours — and it must not be used with a personal or family history of medullary thyroid carcinoma (a rare thyroid cancer) or MEN 2 (an inherited tumour syndrome). 7 In the two phase 3 weight trials, gastrointestinal reactions affected 60–69% of patients against 37% on placebo, mostly mild or moderate and most frequent while the dose was being raised; 8% stopped treatment for adverse reactions against 3% on placebo. 7 Labelled warnings also cover acute pancreatitis, severe gastrointestinal reactions, acute kidney injury from dehydration, low blood sugar (hypoglycaemia) with insulin or a sulfonylurea (a type of diabetes drug), hypersensitivity, diabetic retinopathy (eye disease) complications, gallbladder disease and pulmonary aspiration under anaesthesia (stomach contents entering the lungs). 7

The FDA label rests on two 72-week, placebo-controlled phase 3 trials in 4,740 adults: 3,127 without diabetes and 1,613 with type 2 diabetes. 7 Mean weight change at 72 weeks was −7.4%, −8.3% and −11.1% on 5.5, 9 and 17.2 mg against −2.1% on placebo without diabetes, and −5.1%, −7.0% and −9.6% against −2.5% with type 2 diabetes. 7 In the diabetes trial, glucose below 54 mg/dL occurred in 2% on orforglipron against 0.2% on placebo, and low blood sugar (hypoglycaemia) was reported by 7% of those also taking a sulfonylurea against 0.5% of those not. 7

Keeping it good

How do I store Orforglipron?

Before mixing (powder)

Store FOUNDAYO tablets at room temperature, 20–25°C (68–77°F); brief excursions between 15°C and 30°C (59–86°F) are permitted. 7 Keep them in the original bottle, which comes with a desiccant. 7 Check the expiration date before use.

After mixing (liquid)

Not applicable — FOUNDAYO is a film-coated tablet swallowed whole; there is nothing to reconstitute or mix. 7

Signs it has gone bad

Not our opinion — the published record

What the studies actually found about Orforglipron

2023

Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants

Phase 1a study (a first small safety study) in 92 healthy adults: the half-life (the time the body takes to clear half the drug) was 24.6–35.3 hours after single doses and 48.1–67.5 hours after 4 weeks of daily dosing. Body weight fell by up to 5.4 kg, against 2.4 kg on placebo, over 4 weeks. Most side effects were stomach and gut problems. Dosing needed no water or food restrictions.

Pratt E, Ma X, Liu R, et al.

2026

FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing Information

Approved for long-term weight loss in adults with obesity, or with overweight and at least one weight-related condition. It has a boxed warning (the FDA's strongest warning) for thyroid C-cell tumours. Orforglipron is not active in rodents and caused no rodent tumours. Do not use it if you or your family have had medullary thyroid carcinoma (MTC, a rare thyroid cancer) or MEN 2 (a genetic condition that raises the risk of some tumours), or if you have had a serious allergic reaction to it. Dosing: 0.8 mg once daily, with or without food, then 2.5 mg and 5.5 mg after at least 30 days on each, with optional steps of 9, 14.5 or 17.2 mg (the maximum). In two 72-week phase 3 trials (large final-stage trials), weight fell 7.4%, 8.3% and 11.1% on 5.5, 9 and 17.2 mg vs 2.1% on placebo in people without diabetes, and 5.1%, 7.0% and 9.6% vs 2.5% in people with type 2 diabetes. Most common reactions: nausea (26-35% vs 10%), constipation, diarrhoea, vomiting, dyspepsia (indigestion) and abdominal pain. Absolute bioavailability (the share of the dose that reaches the blood) is 77%; half-life is about 29-49 hours; it is broken down mainly by CYP3A4 (a liver enzyme).

Eli Lilly and Company / U.S. FDA (DailyMed)

2026

Drugs@FDA: FOUNDAYO (orforglipron), NDA 220934

NDA 220934 (a new drug application filed by Eli Lilly and Co): original approval 1 April 2026, a Type 1 new molecular entity (a brand-new drug ingredient); an update to the drug label was approved 4 August 2026.

U.S. Food and Drug Administration

If this isn't the right fit

What people use instead of Orforglipron

Alternative approaches for weight management support

  • Consult your healthcare provider for alternatives to Orforglipron based on your specific needs and medical history

Alternative weight management approaches

  • Semaglutide (Wegovy/Ozempic)
  • Liraglutide (Saxenda)
  • AOD-9604

Non-injectable weight management

  • Oral semaglutide (Rybelsus)
  • Phentermine-topiramate (Qsymia)
  • Lifestyle modifications

Your questions

Orforglipron FAQ

How is orforglipron different from injectable GLP-1 agonists (drugs that copy a gut hormone that controls appetite and blood sugar) like semaglutide?

Orforglipron differs from injectable GLP-1 (a gut hormone that tells your brain you're full) drugs like semaglutide in three ways: (1) It's a small-molecule pill, not an injectable peptide; (2) It binds to a different spot on the GLP-1 receptor (an allosteric site) than the spot used by peptide GLP-1 drugs (the orthosteric site); (3) It uses G protein-biased signaling (it favors one signal path inside the cell), which may reduce receptor desensitization (the receptor responding less over time). The practical advantage is large — it has 77% absolute oral bioavailability (the share that reaches the blood) 7 with no food or water restrictions, compared to injectable semaglutide which requires weekly injections, or oral semaglutide which has <1% bioavailability and requires 30 minutes of fasting.

Did orforglipron beat semaglutide in clinical trials?

Yes. In the head-to-head ACHIEVE-3 Phase 3 trial comparing orforglipron to oral semaglutide in people with type 2 diabetes, orforglipron 36 mg was better at both blood sugar control (HbA1c -2.2% vs -1.4%; HbA1c is a blood test of average blood sugar) and weight loss (-9.2% vs -5.3%). Nearly 3 times more patients reached an HbA1c below 7% with orforglipron 36 mg than with semaglutide 14 mg.

When will orforglipron be available to prescribe?

It already is. The FDA approved orforglipron as FOUNDAYO tablets on 1 April 2026 for long-term weight reduction in adults with obesity, or with overweight and at least one weight-related condition. 78 It is a prescription medicine, and it is not approved for type 2 diabetes. 7

Can patients switch from injectable GLP-1 drugs (drugs that copy a gut hormone that controls appetite and blood sugar) to orforglipron?

Early clinical data from the ATTAIN-Maintain trial suggests patients can successfully maintain weight loss when switching from injectable GLP-1 (a gut hormone that tells your brain you're full) RAs to oral orforglipron. This represents a potentially significant clinical application — patients who achieve their goals with injections could transition to the convenience of an oral pill for long-term maintenance.

Does orforglipron require fasting before taking it?

No. Unlike oral semaglutide, which must be taken on an empty stomach with no more than 4 ounces of water and 30 minutes before eating, orforglipron can be taken at any time regardless of food. Its 77% absolute oral bioavailability (the share that reaches the blood) is not affected by food to a clinically relevant degree 7, making it far more convenient for daily use.

Is orforglipron truly a peptide?

No, orforglipron is technically a peptidomimetic — a non-peptide small molecule (MW 883 Da, a measure of molecular weight) with an indole-oxadiazole core structure. It copies the effect of GLP-1 (a gut hormone that tells your brain you're full) peptides without being a peptide itself. This matters because being a small molecule allows high oral bioavailability (77% 7), a tablet form, easier manufacturing, and potentially lower production costs than peptide-based biologics.

8 sources

References

Every numbered marker on this page points to one of these. Same sources, same numbering as the Orforglipron research profile on Peptide Initiative.

  1. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participantsPratt E, Ma X, Liu R, et al. · 2023
  2. Orforglipron (LY3502970): A Phase 1b study in people with type 2 diabetesPratt E, Ma X, Liu R, et al. · 2023
  3. Orforglipron: A Novel Oral GLP-1 Agonist for Obesity and DiabetesPillai AA, Sharma AM, Krayem H, et al. · 2025
  4. Efficacy and Safety of Oral GLP-1 RA Orforglipron: A Systematic Review and Meta-AnalysisHammad N, Ramadan AM, Nazmy A, et al. · 2026
  5. Efficacy and safety of danuglipron and orforglipron: a systematic review and meta-analysisZhou J, Wang F, Li S, et al. · 2025
  6. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for obesity (ATTAIN-1 phase 3; 6, 12, 36 mg once daily)Lilly ATTAIN-1 / NEJM · 2025
  7. FOUNDAYO (orforglipron) tablets, for oral use — US Prescribing InformationEli Lilly and Company / U.S. FDA (DailyMed) · 2026
  8. Drugs@FDA: FOUNDAYO (orforglipron), NDA 220934U.S. Food and Drug Administration · 2026

Want the deep science?

Read the full Orforglipron research profile

Every claim on this page traces back to the research database behind Peptide Initiative — studies, citations, clinical trial data, and the technical detail we deliberately left out here.

Open the research profile

More weight loss guides

This guide is education, not medical advice. Talk to a clinician before taking anything.